26 results
424B5
ANNX
Annexon Inc
6 Jun 24
Prospectus supplement for primary offering
9:57pm
clinical care outcomes. We plan to present the Phase 3 data at the 2024 Peripheral Nerve Society Annual Meeting on June 25, 2024. We also initiated a
S-3
424B5
ANNX
Annexon Inc
4 Jun 24
Prospectus supplement for primary offering
5:21pm
Nerve Society Annual Meeting on June 25, 2024. We also initiated a
S-3
real-world evidence, or RWE, protocol with International Guillain-Barré Syndrome
8-K
EX-99.1
ANNX
Annexon Inc
4 Jun 24
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
7:05am
to present Phase 3 data at the 2024 Peripheral Nerve Society Annual Meeting on June 25, 2024.
ANX005 has been granted Fast Track and Orphan Drug
8-K
ANNX
Annexon Inc
4 Jun 24
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
7:05am
Society Annual Meeting on June 25, 2024.
GBS is a rapid and acute neurological disease with a narrow therapeutic window that results
8-K
EX-99.1
0vrtyfboi9rkp
4 Mar 24
Regulation FD Disclosure
5:25pm
424B5
frhemixwqz9v9pf3zk
21 Dec 23
Prospectus supplement for primary offering
4:05pm
8-K
EX-99.1
wv06h1
20 Dec 23
Regulation FD Disclosure
5:17pm
8-K
EX-99.3
dvp4z
20 Dec 23
Regulation FD Disclosure
5:17pm
8-K
EX-99.1
ge1h5ew9x0heuipn
13 Nov 23
Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results
4:10pm
8-K
EX-99.1
6slyyl t89fajr
24 Oct 23
Annexon Receives Prime Designation from the Ema for ANX007 for the Treatment of Geographic Atrophy
4:30pm
8-K
EX-99.1
t84lbkdg
7 Aug 23
Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results
4:12pm
8-K
EX-99.2
6j3lt6n
31 Jul 23
Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer
4:30pm
8-K
EX-99.1
ltozgx 2i39s83u
3 Nov 22
Annexon Reports Third Quarter 2022 Financial Results and Plans to Provide Updates on Complement Therapeutic Portfolio in January 2023
6:45am
8-K
EX-99.1
08sum3evv
16 Aug 21
Annexon Biosciences Reports Second Quarter 2021 Financial Results and Provides Mid-Year Business Update
4:11pm
424B4
ctnosni0u0l gaw
24 Jul 20
Prospectus supplement with pricing info
5:15pm